Contributions
Abstract: EP1775
Type: ePoster
Abstract Category: Therapy - disease modifying - 30 Tools for detecting therapeutic response
Background: Teriflunomide is an oral formulation which was approved as first line option for the treatment of Relapsing-Remitent Multiple Sclerosis. Its efficacy and adverse events have been described in randomized controlled trials. Data for regular clinical practice are need. We have been using teriflunomide since july 2015.
Objective: Our objetive is to describe our initial experience with Teriflunomide in terms of tolerance and clinical effectiveness after 1 year of treatment.
Patients and methods: All patients from 7 Clinical Hospitals in Galicia, Spain, who were prescribed Teriflunomide were included, regardless of time on treatment. Basics demographic, clinical data, disability (EDSS scale), number of relapses, adverse events and reasons for discontinuation under teriflunomide were reported.
Results: 139 patients (72,7% woman) were reviewed, 36% naive, average age 42,8 years old (+-9,2), average anual relapse rate (ARR) 0,7 (+-0,7), average EDSS 1,62 (+-1,5). 119 and 64 patients complied 6 and 12 months of treatment. Teriflunomide decrease ARR at 6: 0,11 (+-0,33) and 12 months: 0,19 (+-0,79), p< 0,05. Disability was stable at 6: 1,61 (+-1,4) and 12 months 1,98 (+-1,7), p>0,05. 60 patients (43,2%) experience adverse events, most common gastrointestinal (30,9%), 2 severe (insomnia, elevation ALT) in the first 6 months. 8 patients (5,7%) stopped the treatment in the first 6 months. In the last 6 months 14 patients (10,1%) related adverse events, most common hair thinning (5%), without severe adverse events. 6 patients stopped the treatment in the last 6 months.
Conclusions: The efficacy of teriflunomide in real-life setting was demostrate by the stability in EDSS and reduce the number of relapses. Teriflunomide has been well tolerated by the majority of patients.
Disclosure: This work have not commercial support.
All authors have served as speaker for Biogen Idec, Merck Serono, Genzyme, Novartis and TEVA.
Abstract: EP1775
Type: ePoster
Abstract Category: Therapy - disease modifying - 30 Tools for detecting therapeutic response
Background: Teriflunomide is an oral formulation which was approved as first line option for the treatment of Relapsing-Remitent Multiple Sclerosis. Its efficacy and adverse events have been described in randomized controlled trials. Data for regular clinical practice are need. We have been using teriflunomide since july 2015.
Objective: Our objetive is to describe our initial experience with Teriflunomide in terms of tolerance and clinical effectiveness after 1 year of treatment.
Patients and methods: All patients from 7 Clinical Hospitals in Galicia, Spain, who were prescribed Teriflunomide were included, regardless of time on treatment. Basics demographic, clinical data, disability (EDSS scale), number of relapses, adverse events and reasons for discontinuation under teriflunomide were reported.
Results: 139 patients (72,7% woman) were reviewed, 36% naive, average age 42,8 years old (+-9,2), average anual relapse rate (ARR) 0,7 (+-0,7), average EDSS 1,62 (+-1,5). 119 and 64 patients complied 6 and 12 months of treatment. Teriflunomide decrease ARR at 6: 0,11 (+-0,33) and 12 months: 0,19 (+-0,79), p< 0,05. Disability was stable at 6: 1,61 (+-1,4) and 12 months 1,98 (+-1,7), p>0,05. 60 patients (43,2%) experience adverse events, most common gastrointestinal (30,9%), 2 severe (insomnia, elevation ALT) in the first 6 months. 8 patients (5,7%) stopped the treatment in the first 6 months. In the last 6 months 14 patients (10,1%) related adverse events, most common hair thinning (5%), without severe adverse events. 6 patients stopped the treatment in the last 6 months.
Conclusions: The efficacy of teriflunomide in real-life setting was demostrate by the stability in EDSS and reduce the number of relapses. Teriflunomide has been well tolerated by the majority of patients.
Disclosure: This work have not commercial support.
All authors have served as speaker for Biogen Idec, Merck Serono, Genzyme, Novartis and TEVA.